Evidence item

Independent coverage confirms the 55% response rate as 22 of 40 participants, while noting that this single-arm phase 1b/2 trial had no comparator arm. DIRECT_TEXT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 15899

Source: First-Line Trastuzumab Add-On Reaches 55% Response Rate in HER2-Positive Biliary Tract Cancer · locator {} · excerpt hash sha256:7138d023956f3686e1efe994b4ea83a5c844cff03840a365935a66bc731787df

The trial met its primary endpoint, with an objective response rate of 55% (22 of 40; 95% CI 38.5–70.7) ... There was no comparator arm.